RASH
MCID: EXN002
MIFTS: 57

Exanthem (RASH) malady

Categories: Skin diseases, Infectious diseases

Aliases & Classifications for Exanthem

Summaries for Exanthem

MedlinePlus : 41 a rash is an area of irritated or swollen skin. many rashes are itchy, red, painful, and irritated. some rashes can also lead to blisters or patches of raw skin. rashes are a symptom of many different medical problems. other causes include irritating substances and allergies. certain genes can make people more likely to get rashes. contact dermatitis is a common type of rash. it causes redness, itching, and sometimes small bumps. you get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. some rashes develop right away. others form over several days. although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. if it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to exanthema subitum and viral exanthem. An important gene associated with Exanthem is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Apraclonidine and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are Decreased viability and homeostasis/metabolism

Wikipedia : 71 An exanthem or exanthema (from Greek ἐξάνθημα exánthēma, \"a breaking out\") is a widespread... more...

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
id Related Disease Score Top Affiliating Genes
1 exanthema subitum 12.2
2 viral exanthem 12.0
3 bacterial exanthem 11.8
4 hand, foot and mouth disease 11.2
5 contagious pustular dermatitis 10.8
6 hypersensitivity syndrome, carbamazepine-induced 10.8
7 alcoholic neuropathy 10.4 CD40LG CD79A
8 camptodactyly vertebral fusion 10.4 CD40LG CD79A
9 pineal region mature teratoma 10.3 EGFR ERBB2
10 egg allergy 10.3 CD40LG IL1RN NLRP3
11 dextrocardia 10.3 CD40LG CD79A IL1RN
12 spinal polio 10.3 CD40LG CD79A
13 megacolon 10.3 CD40LG CD79A PTS
14 rabies 10.3 CD40LG CD79A
15 cutaneous sclerosis 10.3 CRP IL1RN NLRP3
16 bile duct disease 10.3 EGFR HRAS KRAS
17 leiomyosarcoma 10.3 CD40LG CD79A CRP
18 unilateral retinoblastoma 10.3 CD40LG CD79A
19 precursor t-lymphoblastic lymphoma/leukemia 10.3 EGFR HRAS KRAS
20 malignant skin fibrous histiocytoma 10.3 HRAS KRAS
21 chronic mucocutaneous candidiasis 10.3 CD40LG CD79A CRP
22 kidney clear cell sarcoma 10.3 EGFR HRAS KRAS
23 ovarian serous cystadenocarcinoma 10.3 CD40LG CD79A CRP
24 mesangial proliferative glomerulonephritis 10.3 CD40LG CD79A
25 cyclotropia 10.3 CD40LG CD79A CRP
26 primary lacrimal atrophy 10.3 CD40LG CD79A TNFRSF1B
27 dermatomycosis 10.3 CD40LG CD79A CRP
28 colonic benign neoplasm 10.3 CD40LG CD79A MTOR
29 glycogen storage disease viii 10.3 CD40LG CD79A CRP
30 artery disease 10.3 CD40LG CD79A CRP
31 myxedema 10.3 EGFR HRAS KRAS
32 spastic entropion 10.3 CD40LG CD79A CRP
33 spastic diplegia infantile type 10.3 EGFR ERBB2 KRAS
34 hemangioma of orbit 10.3 CD40LG CD79A IL2
35 conjunctival vascular disease 10.3 CD40LG CD79A TNFRSF1B
36 delta chain disease 10.3 CD40LG CD79A
37 anomalous left coronary artery from the pulmonary artery 10.2 EGFR ERBB2 MTOR
38 arthus reaction 10.2 ERBB2 HRAS KRAS
39 st. louis encephalitis 10.2 CD40LG IL2 KRAS
40 brachial plexus neuropathy 10.2 EGFR HRAS KRAS
41 acinic cell breast carcinoma 10.2 CD40LG CD79A TNFRSF1B
42 central nervous system origin vertigo 10.2 CD40LG CD79A IL2
43 lymph node adenoid cystic carcinoma 10.2 CD40LG CD79A TNFRSF1B
44 choreatic disease 10.2 CD40LG CD79A TNFRSF1B
45 ovarian cystadenocarcinoma 10.2 EGFR ERBB2 VEGFA
46 vascular hemostatic disease 10.2 EGFR ERBB2 HRAS KRAS
47 trichostrongyloidiasis 10.2 CD40LG CD79A
48 wilkes stevenson syndrome 10.2 CRP IL2 NLRP3
49 anaerobic meningitis 10.2 CD79A EGFR VEGFA
50 endobronchial leiomyoma 10.2 CD40LG CRP IL1RN TNFRSF1B

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.66 HRAS MTOR KRAS EGFR
2 Decreased viability GR00106-A-0 10.66 KRAS
3 Decreased viability GR00221-A-1 10.66 MTOR KRAS PDGFRB EGFR KDR HRAS
4 Decreased viability GR00221-A-2 10.66 KDR KRAS HRAS
5 Decreased viability GR00221-A-3 10.66 KDR HRAS PDGFRB ERBB2
6 Decreased viability GR00221-A-4 10.66 KDR MTOR PDGFRB EGFR ERBB2
7 Decreased viability GR00301-A 10.66 KRAS
8 Decreased viability GR00342-S-1 10.66 MTOR PDGFRB MAP2K7
9 Decreased viability GR00342-S-2 10.66 MTOR
10 Decreased viability GR00381-A-1 10.66 KRAS
11 Decreased cell migration GR00055-A-1 9.8 EGFR HRAS KDR KRAS MTOR PDGFRB
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 EGFR ERBB2 HRAS MTOR PDGFRB VEGFA
13 Decreased viability with paclitaxel GR00179-A-1 9.7 EGFR MTOR ERBB2
14 Decreased viability with paclitaxel GR00179-A-2 9.7 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.7 EGFR MTOR
16 Increased cell migration GR00055-A-3 9.02 EGFR HRAS KDR KRAS MTOR

MGI Mouse Phenotypes related to Exanthem:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.53 APOH CD4 CD40LG CD79A CRP EGFR
2 cellular MP:0005384 10.47 CD4 CD40LG CD79A EGFR ERBB2 IL1RN
3 cardiovascular system MP:0005385 10.45 CD40LG CRP EGFR ERBB2 HRAS IL1RN
4 mortality/aging MP:0010768 10.42 APOH CD4 CD40LG EGFR ERBB2 HRAS
5 growth/size/body region MP:0005378 10.41 KDR KRAS MTOR NLRP3 PDGFRB PTS
6 hematopoietic system MP:0005397 10.4 CD4 CD40LG CD79A EGFR IL1RN IL2
7 endocrine/exocrine gland MP:0005379 10.39 PDGFRB PTS TNFRSF1B VEGFA KRAS MAP2K7
8 immune system MP:0005387 10.38 EGFR IL1RN IL2 KDR KRAS MTOR
9 integument MP:0010771 10.37 KDR KRAS MAP2K7 NLRP3 PDGFRB PTS
10 behavior/neurological MP:0005386 10.35 ERBB2 HRAS IL2 KDR KRAS MAP2K7
11 nervous system MP:0003631 10.31 EGFR ERBB2 HRAS KDR KRAS MAP2K7
12 digestive/alimentary MP:0005381 10.28 CD4 EGFR ERBB2 IL2 KRAS NLRP3
13 normal MP:0002873 10.15 CD79A EGFR ERBB2 HRAS CD4 KDR
14 craniofacial MP:0005382 10.14 HRAS KRAS PDGFRB TNFRSF1B VEGFA EGFR
15 muscle MP:0005369 10.13 KDR KRAS MTOR PDGFRB PTS TNFRSF1B
16 liver/biliary system MP:0005370 10.11 CD79A EGFR IL2 KDR KRAS NLRP3
17 neoplasm MP:0002006 10.11 VEGFA CD79A EGFR ERBB2 HRAS IL2
18 no phenotypic analysis MP:0003012 10.06 CD4 CD79A EGFR HRAS IL2 KDR
19 renal/urinary system MP:0005367 10.02 CD40LG CD79A EGFR HRAS KRAS MTOR
20 reproductive system MP:0005389 10 CD40LG EGFR ERBB2 IL1RN IL2 KRAS
21 respiratory system MP:0005388 9.81 HRAS IL2 KDR KRAS MTOR TNFRSF1B
22 skeleton MP:0005390 9.73 NLRP3 PDGFRB TNFRSF1B CD40LG EGFR ERBB2
23 vision/eye MP:0005391 9.23 EGFR IL2 KDR KRAS MAP2K7 PDGFRB

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 919)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Apraclonidine Approved Phase 4,Phase 3 66711-21-5 2216
2
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
5
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2 94-36-0 7187
6
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 18323-44-9 29029
7
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
8
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
9 sodium fluoride Approved Phase 4,Phase 2 7681-49-4
10
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 1 104987-11-3 445643 439492
11
Salicylic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 69-72-7 338
12
Sorafenib Approved, Investigational Phase 4,Phase 2 284461-73-0 216239 406563
13
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
14
Rifampin Approved Phase 4,Phase 1,Phase 2 13292-46-1 5458213 5381226
15
Sunitinib Approved, Investigational Phase 4,Phase 1 341031-54-7, 557795-19-4 5329102
16
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1 154598-52-4 64139
17
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
18
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1 137-58-6 3676
19
Petrolatum Approved Phase 4,Phase 3,Phase 1,Phase 2 8009-03-8
20
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 564-25-0 54671203
21
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Phase 2 103-90-2 1983
22
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-78-2 2244
23
Azelaic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 123-99-9 2266
24
Benzocaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1994-09-7, 94-09-7 2337
25
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 10118-90-8 5281021
26
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2 378-44-9 9782
27
Pimecrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 137071-32-0 6447131 17753757
28
Ephedrine Approved Phase 4,Phase 2 299-42-3 9294
29
Pseudoephedrine Approved Phase 4,Phase 2 90-82-4 7028
30
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
31
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
32
Azithromycin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 83905-01-5 55185 53477736 447043
33
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2 608141-41-9 11561674
34
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 198153-51-4 5360545
35
Ribavirin Approved Phase 4,Phase 3,Phase 1 36791-04-5 37542
36
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
37
Zinc oxide Approved Phase 4,Phase 3 1314-13-2
38
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
39
Lamivudine Approved, Investigational Phase 4,Phase 2 134678-17-4 60825
40
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
41
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
42
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
43
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
44
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
45
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
46
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
47
Amifostine Approved, Investigational Phase 4 20537-88-6 2141
48
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
49
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
50
Primaquine Approved Phase 4 90-34-6 4908

Interventional clinical trials:

(show top 50) (show all 1717)
id Name Status NCT ID Phase
1 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4
2 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
3 Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma Unknown status NCT01956942 Phase 4
4 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4
5 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
6 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4
7 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4
8 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4
9 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4
10 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4
11 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4
12 Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash Completed NCT00219466 Phase 4
13 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
14 Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients Completed NCT01329731 Phase 4
15 Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients Completed NCT02184299 Phase 4
16 Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study Completed NCT00723515 Phase 4
17 MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study Completed NCT02424097 Phase 4
18 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
19 Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients Completed NCT01768390 Phase 4
20 Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots Completed NCT01149876 Phase 4
21 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants Completed NCT00702507 Phase 4
22 Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity. Completed NCT01195194 Phase 4
23 Efficacy of Pentoxifylline on Chronic Kidney Disease Completed NCT00155246 Phase 4
24 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4
25 Comparison of the Effect of Fluoride Remineralizer Gel and Foam Completed NCT02490592 Phase 4
26 SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle Completed NCT01242852 Phase 4
27 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4
28 Bipolar Study in Adults at Least 18 Years of Age Completed NCT00067938 Phase 4
29 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4
30 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nep Completed NCT00168857 Phase 4
31 FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra Completed NCT01656148 Phase 4
32 Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women Completed NCT00616239 Phase 4
33 Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients Completed NCT00882089 Phase 4
34 Oral Contraceptive Efficacy and Body Weight Completed NCT00662454 Phase 4
35 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail Completed NCT02961998 Phase 4
36 Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) Completed NCT00928577 Phase 4
37 A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Completed NCT02143882 Phase 4
38 Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia Completed NCT00232232 Phase 4
39 Prednisolone Pharmacokinetics in Severe Asthma Completed NCT00662298 Phase 4
40 NOW Thai HAART Study Completed NCT00367731 Phase 4
41 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4
42 Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China Completed NCT02898922 Phase 4
43 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4
44 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4
45 Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis Completed NCT00617643 Phase 4
46 Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa Completed NCT01088516 Phase 4
47 Evaluation of an Herbal-Based De-Pigmenting System Completed NCT02138539 Phase 4
48 Treatment of Lower Extremity Spider Veins With Excel V Completed NCT01362192 Phase 4
49 Fractional CO2 Treatment of Acne Scars in Asians Completed NCT00748462 Phase 4
50 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Genetic Tests for Exanthem

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

39
Skin, T Cells, Testes, Neutrophil, Myeloid, Liver, Prostate

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 248)
id Title Authors Year
1
Urticarial exanthem associated with Capnocytophaga canimorsus bacteremia after a dog bite. ( 27051842 )
2016
2
Eruptive hypomelanosis in a child, a new viral exanthem. ( 26728822 )
2016
3
Anogenital allergic contact dermatitis caused by methylchloroisothiazolinone, methylisothiazolinone and topical clotrimazole with subsequent generalized exanthem triggered by oral fluconazole. ( 27040872 )
2016
4
Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? ( 27103975 )
2016
5
Monitoring of human herpesviruses-6 and -7 DNA in saliva samples during the acute and convalescent phases of exanthem subitum. ( 27648817 )
2016
6
A mini-epidemic of eruptive hypomelanosis in three children of the same family; the first piece of epidemiological evidence for an infectious cause of a novel paraviral exanthem. ( 27038439 )
2016
7
"Tache noire": diagnostic clue in a febrile exanthem. ( 28038854 )
2016
8
Lateralized exanthem mimicking figurate inflammatory dermatosis of infancy after methimazole therapy. ( 27272160 )
2016
9
Image Gallery: A case of unilateral laterothoracic exanthem. ( 27996140 )
2016
10
Stammbetontes Exanthem mit Allgemeinsymptomatik. ( 26972204 )
2016
11
Coxsackievirus A6 Polymorphic Exanthem in Israeli Children. ( 26463513 )
2016
12
Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation. ( 26918962 )
2016
13
Localized exanthem due to echovirus 9. ( 25919440 )
2015
14
Purpuric exanthem caused by Ross River virus infection. ( 25551310 )
2015
15
Unilateral Exanthem. ( 26120168 )
2015
16
Unilateral Laterothoracic Exanthem. ( 26187001 )
2015
17
Febrile Exanthem with Hyperferritinemia. ( 26705442 )
2015
18
Superimposed lateralized exanthem of childhood: report of a case related to adenovirus infection. ( 24635078 )
2014
19
Vesiculobullous viral exanthem due to chikungunya in an infant. ( 25593800 )
2014
20
Unilateral laterothoracic or asymmetric periflexural exanthem: is time to change the name of the disease? ( 25267301 )
2014
21
Eruptive hypomelanosis: a novel exanthem associated with viral symptoms in children. ( 25229328 )
2014
22
Aminopenicillin-associated exanthem: lymphocyte transformation testing revisited. ( 25323308 )
2014
23
Black heel (talon noir) associated with a viral exanthem. ( 24222298 )
2013
24
Unilateral laterothoracic exanthem. ( 21989468 )
2012
25
Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. ( 22290027 )
2012
26
Acetaminophen-induced exanthem of the breasts. ( 22838093 )
2012
27
Febrile illness with papular and vesicular exanthem and ulceronecrotic plaques. ( 23106676 )
2012
28
Histopathology of measles exanthem: a case with characteristic features and eosinophils. ( 22725635 )
2012
29
Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, and papular-purpuric gloves and socks syndrome: a brief review and arguments for diagnostic criteria. ( 24470919 )
2012
30
A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? ( 22082466 )
2011
31
Drug-induced exanthem following dabigatran. ( 21881034 )
2011
32
Asymmetrical periflexural exanthem of childhood with concurrence of molluscum contagiosum infection. ( 21457157 )
2011
33
Papular exanthem discloses acute myeloid leukaemia: interphase fluorescence in situ hybridization revealed deletion of p53 and gain at 8q22/8q24/Tel8q without trisomy 8. ( 19438543 )
2010
34
Transient linear eruption: asymmetric periflexural exanthem or blaschkitis. ( 20609153 )
2010
35
Exanthem with cryopyrin associated periodic syndromes and consideration of IL-1 targeted therapy for neutrophilic predominant urticaria. ( 20657165 )
2010
36
Image in medicine. An exanthem with an annular pattern in a 2-year-old girl. Atypical viral exanthem with an annular pattern. ( 20838712 )
2010
37
Infectious exanthem. ( 19375548 )
2009
38
Unilateral laterothoracic exanthem and primary Epstein-Barr virus infection: case report. ( 19483526 )
2009
39
Symmetrical drug-related intertriginous and flexural exanthem due to oral risperidone. ( 19419476 )
2009
40
Morbilliform exanthem induced by imiquimod in a patient with drug-related immunosuppression. ( 19196306 )
2009
41
Asymmetrical periflexural exanthem exhibiting pseudoisomorphic KAPebner response in an adult. ( 19094120 )
2009
42
Maculopapular exanthem from propolis: case report and review of systemic cutaneous and non-cutaneous reactions. ( 20059499 )
2009
43
An update on pityriasis rosea and other similar childhood exanthems. ( 19502983 )
2009
44
Exanthem subitum-associated encephalitis: nationwide survey in Japan. ( 19818937 )
2009
45
Varicella zoster virus associated acute aseptic meningitis without exanthem in an immunocompetent 14-year-old boy. ( 18316987 )
2008
46
African tick bite fever--papulovesicular exanthem with fever after staying in South Africa. ( 18021248 )
2008
47
Mercury pink exanthem after dental amalgam placement. ( 18269611 )
2008
48
Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem. ( 18566552 )
2008
49
The exanthem of dengue fever: Clinical features of two US tourists traveling abroad. ( 17959270 )
2008
50
Unilateral laterothoracic exanthem with coincident evidence of Epstein-Barr virus reactivation: exploration of a possible link. ( 18319041 )
2008

Variations for Exanthem

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 CD4 CD40LG CD79A CRP EGFR ERBB2
2
Show member pathways
13.93 CD4 CD40LG EGFR ERBB2 HRAS IL2
3
Show member pathways
13.81 CD4 CD79A EGFR ERBB2 HRAS IL2
4
Show member pathways
13.65 CRP EGFR ERBB2 HRAS IL2 KDR
5
Show member pathways
13.61 CD4 CD40LG EGFR ERBB2 HRAS IL2
6
Show member pathways
13.58 EGFR ERBB2 HRAS IL2 KDR KRAS
7
Show member pathways
13.55 CD4 CD40LG CD79A EGFR ERBB2 HRAS
8
Show member pathways
13.54 CD4 EGFR ERBB2 HRAS IL2 KDR
9
Show member pathways
13.43 CD4 CD40LG EGFR ERBB2 HRAS IL2
10
Show member pathways
13.42 CD79A EGFR ERBB2 HRAS IL2 KDR
11
Show member pathways
13.37 EGFR ERBB2 HRAS IL2 KDR KRAS
12
Show member pathways
13.35 CD4 CD40LG EGFR ERBB2 HRAS IL1RN
13
Show member pathways
13.28 CD79A EGFR ERBB2 HRAS IL2 KRAS
14
Show member pathways
13.24 CD4 CD40LG EGFR ERBB2 HRAS IL2
15
Show member pathways
13.15 CD79A EGFR HRAS IL2 KDR KRAS
16
Show member pathways
13.14 EGFR HRAS IL2 KDR KRAS MTOR
17
Show member pathways
13.07 EGFR HRAS IL1RN KRAS MAP2K7 NLRP3
18
Show member pathways
13.05 EGFR ERBB2 HRAS KDR KRAS MAP2K7
19
Show member pathways
12.99 CD79A EGFR HRAS KRAS PDGFRB TNFRSF1B
20
Show member pathways
12.99 EGFR ERBB2 HRAS KRAS MTOR VEGFA
21
Show member pathways
12.97 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
22
Show member pathways
12.97 EGFR ERBB2 HRAS KDR KRAS MAP2K7
23
Show member pathways
12.94 CD4 HRAS KRAS MAP2K7 TNFRSF1B
24
Show member pathways
12.9 ERBB2 HRAS KRAS MAP2K7 MTOR VEGFA
25
Show member pathways
12.89 EGFR HRAS KDR KRAS MAP2K7 MTOR
26
Show member pathways
12.82 EGFR HRAS KDR KRAS PDGFRB VEGFA
27
Show member pathways
12.82 CD79A EGFR ERBB2 HRAS KRAS MTOR
28 12.78 EGFR HRAS KRAS MAP2K7 PDGFRB
29
Show member pathways
12.77 CD40LG EGFR IL2 KDR TNFRSF1B
30 12.76 EGFR ERBB2 HRAS KRAS MTOR PDGFRB
31
Show member pathways
12.72 CD40LG HRAS KDR MAP2K7 TNFRSF1B VEGFA
32
Show member pathways
12.72 CD4 CD40LG CD79A HRAS IL2 MAP2K7
33
Show member pathways
12.69 CD79A HRAS KDR KRAS MAP2K7 VEGFA
34
Show member pathways
12.68 CD4 EGFR ERBB2 HRAS IL2 KRAS
35
Show member pathways
12.65 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
36 12.63 CD40LG CD79A IL1RN IL2 TNFRSF1B
37
Show member pathways
12.6 CD4 CD40LG EGFR HRAS KRAS MAP2K7
38
Show member pathways
12.58 ERBB2 HRAS IL1RN KRAS MTOR
39 12.58 EGFR ERBB2 HRAS KRAS MTOR PDGFRB
40
Show member pathways
12.53 CD4 CD40LG HRAS IL2 KRAS MAP2K7
41
Show member pathways
12.5 EGFR HRAS KRAS MTOR PDGFRB
42
Show member pathways
12.46 EGFR HRAS KDR KRAS